| Document |
Document Title |
|
WO/2023/099327A1 |
The present invention relates to a slow-release formulation. It relates also to the use of said repellent formulation, to a method of use thereof, and to a composition comprising said formulation. It further relates to PMD glucovanillin ...
|
|
WO/2023/094654A1 |
The present invention relates to polyol-derived compounds and processes preparing the same.
|
|
WO/2023/092188A1 |
Compounds and compositions comprising said compounds, which have agrichemical activity such as herbicides, insecticides, fungicides and plant growth regulators; and methods for the use of said compounds.
|
|
WO/2023/094699A1 |
The present disclosure relates to lipid anionic oligosaccharides and to the uses thereof in medicine, especially in the treatment of the pathologies associated with abnormal hyperphosphorylation of tau protein, such as Alzheimer's disease.
|
|
WO/2023/096904A2 |
Provided herein are compound of Formula (I) and (II), and pharmaceutically acceptable salts thereof. Also provided are methods of preparing the compounds, pharmaceutically acceptable compositions thereof, and methods of their use and tre...
|
|
WO/2023/090764A1 |
The present invention relates to a wallpaper composition and wallpaper from which a flavor ingredient is released by heat and, more particularly, to a wallpaper composition and wallpaper, comprising a compound which includes a moiety der...
|
|
WO/2023/091993A1 |
Provided herein are salts which intercalate into the DNA of a cell and are capable of crossing the blood brain barrier of the formula (I) wherein the variables are as defined herein. These salts may be show improved water solubility and/...
|
|
WO/2023/085363A1 |
This transdermal absorption-type patch is provided with a support and an adhesive agent layer laminated on the support. The adhesive agent layer contains: a solid tacrolimus-surfactant composite in which tacrolimus is covered with a surf...
|
|
WO/2023/083716A1 |
The present invention provides anthracycline-linker reagents for the preparation of therapeutic antibody-drug conjugate (ADC) compounds. The present invention also provides therapeutic antibody-drug conjugate (ADC) compounds comprising a...
|
|
WO/2023/083226A1 |
The present invention relates to α-salidroside, and a preparation method therefor and an application thereof. The present invention provides novel salidroside, i.e., α-salidroside. Compared with known β-salidroside, in terms of scaven...
|
|
WO/2023/081505A1 |
The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides formulations and pharmaceutical compositions comprising compounds of the prese...
|
|
WO/2023/070223A1 |
The invention provides for a vaccine against S. suis serotype 2. The vaccine comprises chemically synthesized fragments and thus may be made widely commercially available. The vaccine is used in the livestock production and may be adapte...
|
|
WO/2023/072816A1 |
The invention relates to a multiantennary glycolipid mimetics of formula (I), wherein X, Y, Z and R1 are defined in the description, or a pharmaceutical composition thereof and their use as a medicament, particularly, for the treatment a...
|
|
WO/2023/072085A1 |
The present invention relates to an isopropyl-D-glucopyranoside derivative and a synthesis method therefor. In addition, the derivative can effectively promote the regeneration of cranial nerves and retinal nerves and repair the damage o...
|
|
WO/2023/076044A1 |
This invention relates to end-modified branched block copolymers for soil treatment applications. The end-modified branched block copolymers contain an alkoxylated block copolymer modified with a hydrophobic end group such as an alkysucc...
|
|
WO/2023/074843A1 |
[Problem] The problem of the present invention is to provide: a novel oligosaccharide that can be used in order to manufacture a 2-branched glycan having an α2,6-sialic acid structure at a non-reducing end; a method for manufacturing th...
|
|
WO/2023/067121A1 |
The present disclosure provides a compound of formula I, as well as complexes and compositions comprising a compound of formula I, wherein said compositions and complexes are useful for delivery of certain agents, including, for example,...
|
|
WO/2023/067124A1 |
The present disclosure provides compounds, compositions, and complexes useful for delivery of certain agents, including, for example, nucleic acids.
|
|
WO/2023/066922A1 |
The invention relates to a novel compound, a mixture comprising the compound, a method for producing such a compound, a compound obtained or obtainable by such a method, a mixture comprising one or more such compound(s), a flavour compos...
|
|
WO/2023/065427A1 |
The present invention relates to a glycoside compound, which is named as 2-propenyl guaethol-β-D-glucopyranoside, and has the following structural formula. The present invention further relates to a method for preparing the glycoside co...
|
|
WO/2023/067125A1 |
The present disclosure provides complexes comprising: i) a cationic oligosaccharide comprising one or more cationic moieties bonded to a trehalose, a sucrose, or a gluco-n-oligosaccharide moiety, where n is 2-6; ii) a surfactant; and iii...
|
|
WO/2023/067126A1 |
The present disclosure provides compositions comprising an oligosaccharide of formula (I), wherein said compositions are useful for delivery of certain agents, including, for example, nucleic acids.
|
|
WO/2023/066457A1 |
The invention relates to novel compounds according to formula (I), a method for producing such a compound, a compound obtained or obtainable by such a method, a mixture comprising one or more such compound(s), a composition serving for f...
|
|
WO/2023/062074A1 |
Disclosed is a process for preparing alkyl polyglycosides having a color of less than or equal to 1.5 VCS, the process successively involving: a) a glycosylation step a) consisting in a reaction between at least one alcohol of formula (I...
|
|
WO/2023/062078A1 |
Disclosed is a process for preparing alkyl polyglycosides having a color of less than or equal to 1.5 VCS, the process successively involving: a) a glycosylation step a) consisting in a reaction between at least one alcohol of formula (I...
|
|
WO/2023/062077A1 |
Disclosed is a process for preparing alkyl polyglycosides having a color of less than or equal to 1.5 VCS, the method successively comprising: (a) a glycosylation step (a), consisting in a reaction between at least one alcohol of formula...
|
|
WO/2023/062386A1 |
A process for the synthesis of a glycoside, comprising the step of; performing hydrolysis of a methyl ester glycoside in the presence of a base in water, to form a glycoside, wherein the propensity to reform the methyl ester glycoside is...
|
|
WO/2023/060021A1 |
CD33 ligands which are useful for the synthesis of CD33 ligand-bearing carriers, wherein said CD33 ligand-bearing carriers are directly or indirectly linked to or associated with at least one anti-cancer agent, are described herein. Uses...
|
|
WO/2023/059695A1 |
The present disclosure provides linker compounds of Formula (I) or (II): pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. The present disclosure also relates to uses of the linker compounds, scaffolds, and...
|
|
WO/2023/052616A1 |
The invention relates to sugar amides and mixtures thereof as well as their use incosmetic or household applications and oil or mining applications.
|
|
WO/2023/055588A1 |
A composition and formulation of pheromone that can be extracted from nematode growth medium and a method of use thereof to induce enhanced plant abiotic stress resistance, and/or promote plant growth, when applied to plants, plant parts...
|
|
WO/2023/052829A1 |
The present invention relates to a biotransformation process effected by cultures of a microbial consortium for the preparation of a Quillaja plant extract with antibacterial and cytotoxic properties, comprising one or more monodesmosidi...
|
|
WO/2023/036932A1 |
The present invention relates to a glycocluster comprising at least two acetylated-sialic acids covalently linked to a macrocycle, wherein said macrocycle is selected from porphyrins, pillararenes, calixarenes and fullerenes. According t...
|
|
WO/2023/035350A1 |
The present invention relates to a method for isolating trilobatin and phlorizin from leaves of lithocarpus litseifolius. The method comprises: S1, mixing leaves of lithocarpus litseifolius with an organic solvent at 70-90°C multiple ti...
|
|
WO/2023/039090A1 |
Disclosed herein is a compound and its use for the prognosis or diagnosis of neurodegenerative diseases. The compound has the structure of formula (I), (I). According to embodiments of the present disclosure, the neurodegenerative diseas...
|
|
WO/2023/031948A1 |
Present invention discloses a novel process for extraction of non-toxic, high purity colchicoside from Gloriosa superba and extract thereof. Present invention utilizes a novel non-chromatographic, simple and less timing consuming process...
|
|
WO/2023/034719A1 |
Embodiments of the present application relate to functionalized N-acetylgalactosamine-analogs, methods of making, and uses of the same. In particular, mono or trivalent N-acetylgalactosamine analogs may be prepared by utilizing a wide va...
|
|
WO/2023/032788A1 |
Provided are a protective agent, a surfactant composition, a composition for blood sugar level control, an autophagy inducing agent, a stain for mycobacteria, or a protein extraction agent characterized by containing a compound represent...
|
|
WO/2023/028590A1 |
The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-β1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, a...
|
|
WO/2023/021715A1 |
The sugar-nucleic acid conjugate of the present invention contains a sugar moiety and a nucleic acid moiety. The sugar moiety contains a structure represented by formula (II). The conjugate of the present invention can, for example, effe...
|
|
WO/2023/016999A2 |
GalNAc monomers and GalNAc-oligonucleotide conjugates made using said GalNAc monomers, for example, GalNAc-bearing nucleic acids, e.g. sa-RNAs and siRNAs that may be useful in regulating expression of a target gene.
|
|
WO/2023/018570A1 |
The invention includes a novel method, systems, and compositions for generating a concentrated Aloe vera extract. Embodiments include method, systems, and compositions for extracting a pharmaceutically active polysaccharidic substance fr...
|
|
WO/2023/014938A1 |
The present disclosure provides linker compounds of Formula (I) or (II) pharmaceutically acceptable salts thereof, and related scaffolds and conjugates. More specifically, linker compounds of formulas (l-A), (Il-A) are provided: The pres...
|
|
WO/2023/014760A1 |
The present invention relates, at least in part to, a non-aqueous, solid, or powder formulation composition based on steviol glycosides formed from a genetically modified microbe. Examples of steviol glycosides used in the formulation of...
|
|
WO/2023/002506A1 |
The present invention discloses compositions comprising Sophorolipids, having anti-tubercular activity for potential use in the treatment of tuberculosis and multidrug resistant tuberculosis. The invention also discloses compositions com...
|
|
WO/2023/285367A1 |
The present invention provides the use of a separation process to obtain a product composition comprising at least one sophorolipid, wherein the product composition achieves a negative result under the h-CLAT assay according to OECD 442E...
|
|
WO/2023/281040A1 |
The present invention relates to novel bi-functionalized trans-cyclooctenes of formula (I). It also relates to conjugates, compositions, medical uses of such compounds, and methods for producing such compounds as well as conjugates of su...
|
|
WO/2023/280257A1 |
The present invention belongs to the field of microbial fermentation, and specifically provides a pretreatment process for an acarbose fermentation liquid. By means of successively adding a filter aid twice, adjusting the pH with an acid...
|
|
WO/2023/277680A1 |
Methods of preparing highly purified steviol glycosides are described. The methods include utilizing enzyme preparations and recombinant microorganisms for converting various starting compositions to target steviol glycosides. The highly...
|
|
WO/2023/278801A1 |
The present invention provides glycolipid-heavy metal ion complexes, composition useful for forming glycolipid-heavy metal ion complexes, and methods for separating metal ion(s) from a sample using glycolipids.
|
